Global Cancer Care Market, By Treatment Type (Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy, Other Treatment Types), Cancer Type (Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Respiratory/Lung Cancer, Other Cancer Types), End User (Hospitals, Specialty Clinics, Cancer and Radiation Therapy Centers), Therapeutic Class (G-CSFs, Bisphosphonates, Antiemetic, Opioids, NSAIDs, ESAs) – Industry Trends and Forecast to 2029.
Cancer Care Market Analysis and Size
Clinical research, healthcare, physical examination, self-care, disease diagnosis and treatment, drug and device therapy, surgical treatment, hospital management, pharmacy, quality control in medicine, and disease prevention are all considered in cancer care. Cancer is the world's second leading cause of death, accounting for an estimated 9.6 million deaths, or one in every six, in 2018. Men are more likely to develop lung, prostate, colorectal, stomach, and liver cancers, while women are more likely to develop breast, colorectal, lung, cervical, and thyroid cancers.
Data Bridge Market Research analyses that the cancer care market which was USD 170 billion in 2021, is expected to reach USD 351.37 billion by 2029, at a CAGR of 9.50% during the forecast period 2022 to 2029. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Cancer Care Market Scope and Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2022 to 2029
|
|
Base Year
|
2021
|
|
Historic Years
|
2020 (Customizable to 2014 - 2019)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Treatment Type (Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy, Other Treatment Types), Cancer Type (Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Respiratory/Lung Cancer, Other Cancer Types), End User (Hospitals, Specialty Clinics, Cancer and Radiation Therapy Centers), Therapeutic Class (G-CSFs, Bisphosphonates, Antiemetic, Opioids, NSAIDs, ESAs)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
|
|
Market Players Covered
|
Astellas Pharma US, Inc. (U.S.), Johnson & Johnson Services, Inc (U.S.), Sanofi (France), Ipsen Pharma (France), AbbVie Inc. (U.S.), Myovant Sciences GmbH (U.K.), Bayer AG (Germany), AstraZeneca (U.K.), Tolmar Pharmaceuticals, Inc. (U.S.), Ferring B.V. (Switzerland), Takeda Pharmaceutical Company Limited (Japan), Teva Pharmaceutical Industries Ltd. (Israel), Pfizer Inc (U.S.), Dendreon Pharmaceuticals LLC. (U.S.), Bristol-Myers Squibb Company (U.S.), Abbott (U.S.), GSK plc (U.K.), F. Hoffmann-La Roche Ltd (Switzerland), Genentech, Inc (U.S.) and Novartis AG (Switzerland)
|
|
Market Opportunities
|
|
Market Definition
Cancer is a disease in which certain cells in the body grow uncontrollably and spread to other parts of the body. Cancer can develop almost anywhere in the human body, which contains trillions of cells. Human cells normally grow and multiply (a process known as cell division) to form new cells as the body requires them. Cells die when they become old or damaged, replacing new cells.
Global Cancer Care Market Dynamics
Drivers
- The elderly population is more prone to cancer
Hospital outpatient evaluation and management (E&M) visits fell by 74%, new patient E&M visits fell by 70%, and current patient E&M visits fell by 60%. The overall condition returned to normal around the second quarter of 2021. The rising cancer incidence and population ageing are two of the most important factors driving market growth. Globocan predicts that the number of new cancer cases will rise by 47% from 2020 to 28.4 million over the next two decades. Furthermore, the elderly are more vulnerable to cancer, and life expectancy in developing countries has surpassed 80 years. These are the certain factors which help the market to grow.
- Increased cancer prevalence and unfavourable effects
The market for cancer care is being driven by a number of factors, including the rising incidence of cancer and the negative side effects associated with cancer drug use, as well as an increase in the global elderly population. Furthermore, an increase in the use of biosimilars and an increase in government healthcare spending contribute to the growth of the market for cancer-supportive care medications.
Opportunities
- Increase in targeted therapy medication advancements
Patients and medical professionals now prefer these treatments over others because they have fewer side effects than other options. This is due to increased research and development of targeted therapy medications in recent years. As a result, there will be a direct impact on expanding the market for pharmaceuticals used in supportive cancer care.
Restraints/Challenges
- Side effects associated with targeted therapy medications
The discovery and preference of targeted therapy medications with fewer side effects by patients and physicians, which directly impacts the growth of the cancer care market, may hamper the industry's growth. Furthermore, the lengthy approval process for biosimilar also hamper market growth.
This cancer care market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the cancer care market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Recent developments
- In June 2022, Heron Therapeutics Announced the Publication of ZYNRELEF as the Foundation of a Perioperative Non-Opioid Multimodal Analgesic Regimen Reduced Severe Pain and Opioid Use in Patients Having Total Knee Arthroplasty.
- In March 2022, Heron Therapeutics obtained Pass-through Payment Status for ZYNRELEF from the Centers for Medicare & Medicaid Services, allowing for separate reimbursement in the hospital outpatient setting of care.
Global Cancer Care Market Scope
The cancer care market is segmented on the basis of treatment type, cancer type, end users and therapeutic class. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Treatment Type
- Chemotherapy
- Targeted Therapy
- Immunotherapy
- Hormonal Therapy
- Other Treatment Types
Cancer Type
- Blood Cancer
- Breast Cancer
- Prostate Cancer
- Gastrointestinal Cancer
- Gynecologic Cancer
- Respiratory/Lung Cancer
- Other Cancer Types
End User
- Hospitals
- Specialty Clinics
- Cancer and Radiation Therapy Centers
Therapeutic Class
- G-CSFs
- Bisphosphonates
- Antiemetic
- Opioids
- NSAIDs
- ESAs
Cancer Care Market Regional Analysis/Insights
The cancer care market is analyzed and market size insights and trends are provided by country, treatment type, cancer type, end users and therapeutic class as referenced above.
The countries covered in the cancer care market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
North America dominates the cancer care market due to the rise in global geriatric population and government expenditures on healthcare.
Asia-Pacific is expected to grow at the highest growth rate in the forecast period of 2022 to 2029 owing to an increase in cancer patients. The Middle East, Africa, and Latin America are expected to grow in the cancer care market due to rising cancer treatment awareness in these countries.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Cancer Care Market Share Analysis
The cancer care market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to cancer care market.
Some of the major players operating in the cancer care market are:
- Astellas Pharma US, Inc. (U.S.)
- Johnson & Johnson Services, Inc (U.S.)
- Sanofi (France)
- Ipsen Pharma (France)
- AbbVie Inc. (U.S.)
- Myovant Sciences GmbH (U.K.)
- Bayer AG (Germany)
- AstraZeneca (U.K.)
- Tolmar Pharmaceuticals, Inc. (U.S.)
- Ferring B.V. (Switzerland)
- Takeda Pharmaceutical Company Limited (Japan)
- Teva Pharmaceutical Industries Ltd. (Israel)
- Pfizer Inc (U.S.)
- Dendreon Pharmaceuticals LLC. (U.S.)
- Bristol-Myers Squibb Company (U.S.)
- Abbott (U.S.)
- GSK plc (U.K.)
- F. Hoffmann-La Roche Ltd (Switzerland)
- Genentech, Inc (U.S.)
- Novartis AG (Switzerland)
SKU-